Lotus Eye Hospit (LOTUSEYE)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹127.05, Lotus Eye Hospit is a business I would circle but not buy. The balance sheet is conservative—debt/equity is just 0.08—and sales grew 10.61%, but that is where the good news ends. This company earned an ROE of only 1.08% and ROCE of 2.99%. In the latest quarter, sales were ₹14 Cr and net profit was essentially ₹0 Cr. Over the year, profit actually fell 8.33%. As Graham said, the stock market is a voting machine in the short run and a weighing machine in the long run; on these numbers, the weighing machine says the business generates almost no earnings. The market cap is ₹229 Cr, so investors are paying about 352 times earnings and 4.51 times book value for a business that earns almost nothing. Book value is only ₹28.17. There is no dividend yield, so minority shareholders receive no cash while waiting. The Piotroski F-score of 4/9 raises further doubts about financial strength. Promoter holding of 39.67% is decent, but it does not compensate for weak profitability. The 52-week range of ₹75.51 to ₹153.00 shows a volatile speculative stock, not a stable compounding machine. Is this a turnaround? Possibly, if margins recover and profit turns positive. But I do not pay a premium for 'possibly.' I need a margin of safety—at 127 rupees, there is none for an owner with such low return on capital.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer